Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Equities research analysts at Leerink Partnrs cut their FY2026 earnings per share (EPS) estimates for Arrowhead ...

Arrowhead Pharmaceuticals’ phase 1/2a study has found the company’s investigational RNA interference (RNAi) candidate was ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clini ...

US Bancorp DE cut its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 14.0% during the ...

H.C. Wainwright reiterates a Buy rating and $80 price target on shares of Arrowhead (ARWR) Pharmaceuticals after the company announced top-line ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...

In trading on Thursday, shares of Arrowhead Pharmaceuticals Inc (Symbol: ARWR) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $14.87 per share.

In a report released today, Keay Nakae from Chardan Capital maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...